DROXIA

Manufacturer
E.R. Squibb & Sons, L.L.C.
Effective date
2022-11-15
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
19
Source
legacy-cache
Hydrated at
2026-08-01 21:46:18

Label at a glance#

ProductDROXIA
Active ingredienthydroxyurea
Label structure22 sections

Boxed warning

Myelosuppression: DROXIA may cause severe myelosuppression. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary [see Warnings and Precautions (5.1) ] . Malignancies:  DROXIA is carcinogenic. Advise sun protection and monitor patients for malignancies [see Warnings and Precautions (5.3) ] .

Indications and uses

DROXIA is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in patients with sickle cell anemia with recurrent moderate to severe painful crises.

Dosage and administration

Table 1:     Dosing Recommendation Based on Blood Count Dosing Regimen Dose Dose Modification Criteria Monitoring Parameters Initial Recommended Dosing 15 mg/kg/day as a single dose once daily based on the patient’s actual or ideal weight, whichever is less.  Monitor the patient’s blood count every 2 weeks [see Warnings and Precautions ( 5.1 )]. Dosing Based on Blood Counts   In an acceptable   range Increase dose...

Storage and handling

DROXIA ® (hydroxyurea capsules, USP) is supplied in HDPE bottles with a plastic safety screw cap. Each bottle contains 60 capsules. DROXIA is supplied in the following strengths: 200 mg opaque blue-green capsules, marked in black ink with “ DROXIA ” and “ 6335 ” (NDC 0003-6335-17). 300 mg opaque purple capsules, marked in black ink with “ DROXIA ” and “ 6336 ” (NDC 0003-6336-17). 400 mg opaque reddish-orange capsu...

Label contents#

Full prescribing information#

WARNING: MYELOSUPPRESSION AND MALIGNANCIES

Boxed Warning section

Myelosuppression: DROXIA may cause severe myelosuppression. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary [see Warnings and Precautions (5.1)].

Malignancies: DROXIA is carcinogenic. Advise sun protection and monitor patients for malignancies [see Warnings and Precautions (5.3)].

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

DROXIA is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in patients with sickle cell anemia with recurrent moderate to severe painful crises.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.1 Dosing Information

SPL UNCLASSIFIED SECTION

Table 1:     Dosing Recommendation Based on Blood Count

Dosing Regimen

Dose

Dose Modification Criteria

Monitoring Parameters

Initial Recommended
Dosing

15 mg/kg/day as a single dose once daily based on the patient’s actual or ideal weight, whichever is less.

 Monitor the patient’s blood count every 2 weeks [see Warnings and Precautions (5.1)].

Dosing Based on
Blood Counts

  In an acceptable
  range

Increase dose
5 mg/kg/day every 12 weeks

Maximal dose:
35 mg/kg/day*

*Maximal dose is the highest dose that does not produce toxic blood counts over 24 consecutive weeks.

Increase dosing only if blood counts are in an acceptable range.

Do not increase if myelosuppression occurs.

Blood Counts Acceptable Range

neutrophils ≥2500 cells/mm3

platelets ≥95,000/mm3

hemoglobin >5.3 g/dL

reticulocytes ≥95,000/mm3 if
    the hemoglobin
    concentration <9 g/dL

  Between acceptable
  and toxic range

Do not increase dose.

If blood counts are considered toxic, discontinue DROXIA until hematologic recovery.

Blood Counts Toxic Range

neutrophils <2000 cells/mm3

platelets <80,000/mm3

hemoglobin <4.5 g/dL

reticulocytes <80,000/mm3 if
    the hemoglobin
    concentration <9 g/dL

Dosing After
Hematologic
Recovery

Reduce dose by
2.5 mg/kg/day.

Reduce the dose from the dose associated with hematologic toxicity.

May titrate up or down every 12 weeks in 2.5 mg/kg/day increments.

The patient should be at a stable dose with no hematologic toxicity for 24 weeks.

Discontinue the treatment permanently if a patient develops hematologic toxicity twice.

Swallow DROXIA capsules whole. Do NOT open, break, or chew capsules because DROXIA is a cytotoxic drug. Patients must be able to follow directions regarding drug administration and their monitoring and care.

Fetal hemoglobin (HbF) levels may be used to evaluate the efficacy of DROXIA in clinical use. Obtain HbF levels every three to four months. Monitor for an increase in HbF of at least two-fold over the baseline value.

DROXIA causes macrocytosis, which may mask the incidental development of folic acid deficiency. Prophylactic administration of folic acid is recommended.

DROXIA is a cytotoxic drug. Follow applicable special handling and disposal procedures [see References (15)].

2.2 Dose Modifications for Renal Impairment

SPL UNCLASSIFIED SECTION

Reduce the dose of DROXIA by 50% in patients with creatinine clearance of less than 60 mL/min or with end-stage renal disease (ESRD) [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]. Creatinine clearance values were obtained using 24-hour urine collections.

*  On dialysis days, administer DROXIA to patients with ESRD following hemodialysis.

Creatinine Clearance

(mL/min)

Recommended DROXIA Initial Dose

(mg/kg once daily)

≥60

15

<60 or ESRD*

7.5

Monitor the hematologic parameters closely in these patients.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Capsules:

  • ​​200 mg opaque blue-green capsules, imprinted with black ink “DROXIA” and “6335”.
  • 300 mg opaque purple capsules, imprinted with black ink “DROXIA” and “6336”.
  • 400 mg opaque reddish-orange capsules, imprinted with black ink “DROXIA” and “6337”.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

DROXIA is contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of its formulation.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Myelosuppression

SPL UNCLASSIFIED SECTION

Hydroxyurea causes severe myelosuppression. Treatment with DROXIA should not be initiated if bone marrow function is markedly depressed. Bone marrow suppression may occur, and leukopenia is generally its first and most common manifestation. Thrombocytopenia and anemia occur less often, and are seldom seen without a preceding leukopenia.

Some patients, treated at the recommended initial dose of 15 mg/kg/day, have experienced severe or life-threatening myelosuppression.

Evaluate hematologic status prior to and during treatment with DROXIA. Provide supportive care and modify dose or discontinue DROXIA as needed. Recovery from myelosuppression is usually rapid when therapy is interrupted.

5.2  Hemolytic Anemia

SPL UNCLASSIFIED SECTION

Cases of hemolytic anemia in patients treated with hydroxyurea for myeloproliferative diseases have been reported [see Adverse Reactions (6.1) ]. Patients who develop acute jaundice or hematuria in the presence of persistent or worsening of anemia should have laboratory tests evaluated for hemolysis (e.g., measurement of serum lactate dehydrogenase, haptoglobin, reticulocyte, unconjugated bilirubin levels, urinalysis, and direct and indirect antiglobulin [Coombs] tests). In the setting of confirmed diagnosis of hemolytic anemia and in the absence of other causes, discontinue DROXIA.

5.3 Malignancies

SPL UNCLASSIFIED SECTION

Hydroxyurea is a human carcinogen. In patients receiving long-term hydroxyurea for myeloproliferative disorders, secondary leukemia has been reported. 

Secondary leukemia has also been reported in patients treated with long-term hydroxyurea for sickle cell disease. Leukemia has also been reported in patients with sickle cell disease and no prior history of treatment with hydroxyurea.

All patients using DROXIA should be followed up on a long-term basis with regular blood counts to detect development of leukemia.

Skin cancer has also been reported in patients receiving long-term hydroxyurea. Advise protection from sun exposure and monitor for the development of secondary malignancies.

5.4 Embryo-Fetal Toxicity

SPL UNCLASSIFIED SECTION

Based on the mechanism of action and findings in animals, DROXIA can cause fetal harm when administered to a pregnant woman. Hydroxyurea was embryotoxic and teratogenic in rats and rabbits at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m2 basis. Advise pregnant women of the potential risk to a fetus [see Use in Specific Populations (8.1)].
Advise females of reproductive potential to use effective contraception during and after treatment with DROXIA for at least 6 months after therapy. Advise males of reproductive potential to use effective contraception during and after treatment with DROXIA for at least 1 year after therapy [see Use in Specific Populations (8.1, 8.3)].

5.5 Vasculitic Toxicities

SPL UNCLASSIFIED SECTION

Cutaneous vasculitic toxicities, including vasculitic ulcerations and gangrene, have occurred in patients with myeloproliferative disorders during therapy with hydroxyurea. These vasculitic toxicities were reported most often in patients with a history of, or currently receiving, interferon therapy. If cutaneous vasculitic ulcers occur, institute treatment and discontinue DROXIA.

5.6 Live Vaccinations

SPL UNCLASSIFIED SECTION

Avoid use of live vaccine in patients taking DROXIA. Concomitant use of DROXIA with a live virus vaccine may potentiate the replication of the virus and/or may increase the adverse reaction of the vaccine because normal defense mechanisms may be suppressed by DROXIA. Vaccination with live vaccines in a patient receiving DROXIA may result in severe infection. Patient’s antibody response to vaccines may be decreased. Consider consultation with a specialist.

5.7 Risks with Concomitant Use of Antiretroviral Drugs

SPL UNCLASSIFIED SECTION

Pancreatitis, hepatotoxicity, and peripheral neuropathy have occurred when hydroxyurea was administered concomitantly with antiretroviral drugs, including didanosine and stavudine [see Drug Interactions (7.1)].

5.8 Macrocytosis

SPL UNCLASSIFIED SECTION

DROXIA may cause macrocytosis, which is self-limiting, and is often seen early in the course of treatment. The morphologic change resembles pernicious anemia, but is not related to vitamin B12 or folic acid deficiency. This may mask the diagnosis of pernicious anemia. Prophylactic administration of folic acid is recommended.

5.9 Pulmonary Toxicity

SPL UNCLASSIFIED SECTION

Interstitial lung disease including pulmonary fibrosis, lung infiltration, pneumonitis, and alveolitis/allergic alveolitis (including fatal cases) have been reported in patients treated for myeloproliferative neoplasm. Safety and effectiveness have not been established for the use of DROXIA in the treatment of myeloproliferative neoplasms and the use is not approved by the FDA. Monitor patients developing pyrexia, cough, dyspnea, or other respiratory symptoms frequently, investigate and treat promptly. Discontinue DROXIA and manage with corticosteroids. [see Adverse Reactions (6.1) ].

5.10 Laboratory Test Interference

SPL UNCLASSIFIED SECTION

Interference with Uric Acid, Urea, or Lactic Acid Assays is possible, rendering falsely elevated results of these in patients treated with hydroxyurea [see Drug Interactions (7.2)].

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following clinically significant adverse reactions are described in detail in other labeling sections:

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

6.1 Clinical Trial Experience

SPL UNCLASSIFIED SECTION

In 299 patients treated for sickle cell anemia in the Multicenter Study of Hydroxyurea in Sickle Cell Anemia, the most common adverse reactions were hematologic, with neutropenia, and low reticulocyte and platelet levels necessitating temporary cessation in almost all patients. Hematologic recovery usually occurred in two weeks.

Other adverse reactions include hair loss, macrocytosis, bleeding, and melanonychia.

6.2 Postmarketing Experience

SPL UNCLASSIFIED SECTION

The following adverse reactions have been identified during post-approval use of hydroxyurea in the treatment of neoplastic diseases. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.

  • Reproductive System and Breast disorders: azoospermia, and oligospermia
  • Gastrointestinal disorders: stomatitis, nausea, vomiting, diarrhea, and constipation
  • Metabolism and Nutrition disorders: anorexia
  • Skin and subcutaneous tissue disorders: maculopapular rash, skin ulceration, cutaneous lupus erythematosus, dermatomyositis-like skin changes, peripheral and facial erythema, hyperpigmentation, nail hyperpigmentation, atrophy of skin and nails, scaling, violet papules, and alopecia
  • Renal and urinary disorders: dysuria, elevations in serum uric acid, blood urea nitrogen (BUN), and creatinine levels
  • Nervous system disorders: headache, dizziness, drowsiness, disorientation, hallucinations, and convulsions
  • General disorders: fever, chills, malaise, edema, and asthenia
  • Hepatobiliary disorders: elevation of hepatic enzymes, cholestasis, and hepatitis
  • Respiratory disorders: diffuse pulmonary infiltrates, dyspnea, and pulmonary fibrosis, interstitial lung disease, pneumonitis, alveolitis, allergic alveolitis and cough
  • Immune disorders: systemic lupus erythematosus
  • Hypersensitivity: Drug-induced fever (pyrexia) (>39°C, >102°F) requiring hospitalization has been reported concurrently with gastrointestinal, pulmonary, musculoskeletal, hepatobiliary, dermatological or cardiovascular manifestations. Onset typically occurred within 6 weeks of initiation and resolved upon discontinuation of hydroxyurea. Upon re-administration fever re-occurred typically within 24 hours.
  • Blood and lymphatic system disorders: hemolytic anemia

7 DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

7.1 Increased Toxicity with Concomitant Use of Antiretroviral Drugs

SPL UNCLASSIFIED SECTION

Pancreatitis

SPL UNCLASSIFIED SECTION

In patients with HIV infection during therapy with hydroxyurea and didanosine, with or without stavudine, fatal and nonfatal pancreatitis have occurred. Hydroxyurea is not indicated for the treatment of HIV infection; however, if patients with HIV infection are treated with hydroxyurea, and in particular, in combination with didanosine and/or stavudine, close monitoring for signs and symptoms of pancreatitis is recommended. Permanently discontinue therapy with DROXIA in patients who develop signs and symptoms of pancreatitis.

Hepatotoxicity

SPL UNCLASSIFIED SECTION

Hepatotoxicity and hepatic failure resulting in death have been reported during postmarketing surveillance in patients with HIV infection treated with hydroxyurea and other antiretroviral drugs. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. Avoid this combination.

Peripheral Neuropathy

SPL UNCLASSIFIED SECTION

Peripheral neuropathy, which was severe in some cases, has been reported in patients with HIV infection receiving hydroxyurea in combination with antiretroviral drugs, including didanosine, with or without stavudine.

7.2 Laboratory Test Interference

SPL UNCLASSIFIED SECTION

Interference with Uric Acid, Urea, or Lactic Acid Assays

SPL UNCLASSIFIED SECTION

Studies have shown that there is an analytical interference of hydroxyurea with the enzymes (urease, uricase, and lactate dehydrogenase) used in the determination of urea, uric acid, and lactic acid, rendering falsely elevated results of these in patients treated with hydroxyurea.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary

TERATOGENIC EFFECTS SECTION

DROXIA can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see Clinical Pharmacology (12.1)]. There are no data with DROXIA use in pregnant women to inform a drug-associated risk. In animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m2 basis (see Data). Advise women of the potential risk to a fetus and to avoid becoming pregnant while being treated with DROXIA.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively.

Data

SPL UNCLASSIFIED SECTION

Animal Data

SPL UNCLASSIFIED SECTION

Hydroxyurea has been demonstrated to be a potent teratogen in a wide variety of animal models, including mice, hamsters, cats, miniature swine, dogs, and monkeys at doses within 1-fold of the human dose given on a mg/m2 basis. Hydroxyurea is embryotoxic and causes fetal malformations (partially ossified cranial bones, absence of eye sockets, hydrocephaly, bipartite sternebrae, missing lumbar vertebrae) at 180 mg/kg/day (about 0.8 times the maximum recommended human daily dose on a mg/m2 basis) in rats and at 30 mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m2 basis) in rabbits. Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and developmental delays. Hydroxyurea crosses the placenta. Single doses of ≥375 mg/kg (about 1.7 times the maximum recommended human daily dose on a mg/m2 basis) to rats caused growth retardation and impaired learning ability.

8.2 Lactation

LACTATION SECTION

Risk Summary

SPL UNCLASSIFIED SECTION

Hydroxyurea is excreted in human milk. Because of the potential for serious adverse reactions in a breastfed infant from hydroxyurea, including carcinogenicity, discontinue breastfeeding during treatment with DROXIA.

8.3 Females and Males of Reproductive Potential

FEMALES & MALES OF REPRODUCTIVE POTENTIAL SECTION

Pregnancy Testing

SPL UNCLASSIFIED SECTION

Verify the pregnancy status of females of reproductive potential prior to initiating DROXIA therapy.

Contraception

SPL UNCLASSIFIED SECTION

Females

SPL UNCLASSIFIED SECTION

DROXIA can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during and after treatment with DROXIA for at least 6 months after therapy. Advise females to immediately report pregnancy.

Males

SPL UNCLASSIFIED SECTION

DROXIA may damage spermatozoa and testicular tissue, resulting in possible genetic abnormalities. Males with female sexual partners of reproductive potential should use effective contraception during and after treatment with DROXIA for at least 1 year after therapy [see Nonclinical Toxicology (13.1)].

Infertility

SPL UNCLASSIFIED SECTION

Males

SPL UNCLASSIFIED SECTION

Based on findings in animals and humans, male fertility may be compromised by treatment with DROXIA. Azoospermia or oligospermia, sometimes reversible, has been observed in men. Inform male patients about the possibility of sperm conservation before the start of therapy [see Adverse Reactions (6) and Nonclinical Toxicology (13.1)].

8.4 Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use

SPL UNCLASSIFIED SECTION

Clinical studies of DROXIA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Elderly patients may be more sensitive to the effects of hydroxyurea and may require a lower dose regimen. Hydroxyurea is excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.2)].

8.6 Renal Impairment

SPL UNCLASSIFIED SECTION

The exposure to hydroxyurea is higher in patients with creatinine clearance of less than 60 mL/min. Reduce dosage and closely monitor the hematologic parameters when DROXIA is to be administered to these patients [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)].

8.7 Hepatic Impairment

SPL UNCLASSIFIED SECTION

There are no data that support specific guidance for dosage adjustment in patients with hepatic impairment. Close monitoring of hematologic parameters is advised in these patients.

10 OVERDOSAGE

OVERDOSAGE SECTION

Acute mucocutaneous toxicity has been reported in patients receiving hydroxyurea at dosages several times the therapeutic dose. Soreness, violet erythema, edema on palms and soles followed by scaling of hands and feet, severe generalized hyperpigmentation of the skin, and stomatitis have been observed.

11 DESCRIPTION

DESCRIPTION SECTION

DROXIA® (hydroxyurea capsules, USP) is available for oral use as capsules containing 200 mg, 300 mg, and 400 mg hydroxyurea. Inactive ingredients include citric acid, gelatin, lactose, magnesium stearate, sodium phosphate, titanium dioxide, and capsule colorants: FD&C Blue No. 1 and FD&C Green No. 3 (200 mg capsules); D&C Red No. 28, D&C Red No. 33, and FD&C Blue No. 1 (300 mg capsules); D&C Red No. 28, D&C Red No. 33, and D&C Yellow No. 10 (400 mg capsules).

Hydroxyurea is a white to off-white crystalline powder. It is hygroscopic and freely soluble in water, but practically insoluble in alcohol. The empirical formula is CH4N2O2 and it has a molecular weight of 76.05. Its structural formula is:

Hydroxyurea Chemical Structure
Hydroxyurea Chemical Structure

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

The precise mechanism by which hydroxyurea produces its cytotoxic and cytoreductive effects is not known. However, various studies support the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein.

The mechanisms by which DROXIA produces its beneficial effects in patients with sickle cell anemia (SCA) are uncertain. Known pharmacologic effects of DROXIA that may contribute to its beneficial effects include increasing hemoglobin F levels in red blood cells (RBCs), decreasing neutrophils, increasing the water content of RBCs, increasing deformability of sickled cells, and altering the adhesion of RBCs to endothelium.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

Absorption

SPL UNCLASSIFIED SECTION

Following oral administration of DROXIA, hydroxyurea reaches peak plasma concentrations in 1 to 4 hours. Mean peak plasma concentrations and AUCs increase more than proportionally with increase of dose.

There are no data on the effect of food on the absorption of hydroxyurea.

Distribution

SPL UNCLASSIFIED SECTION

Hydroxyurea distributes throughout the body with a volume of distribution approximating total body water.

Hydroxyurea concentrates in leukocytes and erythrocytes.

Metabolism

SPL UNCLASSIFIED SECTION

Up to 60% of an oral dose undergoes conversion through saturable hepatic metabolism and a minor pathway of degradation by urease found in intestinal bacteria.

Excretion

SPL UNCLASSIFIED SECTION

In patients with sickle cell anemia, the mean cumulative urinary recovery of hydroxyurea was about 40% of the administered dose.

Specific Populations

SPL UNCLASSIFIED SECTION

Renal Impairment

SPL UNCLASSIFIED SECTION

The effect of renal impairment on the pharmacokinetics of hydroxyurea was assessed in adult patients with sickle cell disease and renal impairment. Patients with normal renal function (creatinine clearance [CrCl] >80 mL/min), mild (CrCl 50-80 mL/min), moderate (CrCl =30-<50 mL/min), or severe (<30 mL/min) renal impairment received a single oral dose of 15 mg/kg hydroxyurea. Creatinine clearance values were obtained using 24-hour urine collections. Patients with ESRD received two doses of 15 mg/kg separated by 7 days; the first was given following a 4-hour hemodialysis session, the second prior to hemodialysis. The exposure to hydroxyurea (mean AUC) in patients with CrCl <60 mL/min and those with ESRD was 64% higher than in patients with normal renal function (CrCl >60 mL/min). Reduce the dose of DROXIA when it is administered to patients with creatinine clearance of <60 mL/min or with ESRD following hemodialysis [see Dosage and Administration (2.2) and Use in Specific Populations (8.6)].

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

SPL UNCLASSIFIED SECTION

Conventional long-term studies to evaluate the carcinogenic potential of DROXIA have not been performed. However, intraperitoneal administration of 125 to 250 mg/kg hydroxyurea (about 0.6-1.2 times the maximum recommended human oral daily dose on a mg/m2 basis) thrice weekly for 6 months to female rats increased the incidence of mammary tumors in rats surviving to 18 months compared to control. Hydroxyurea is mutagenic in vitro to bacteria, fungi, protozoa, and mammalian cells. Hydroxyurea is clastogenic in vitro (hamster cells, human lymphoblasts) and in vivo (SCE assay in rodents, mouse micronucleus assay). Hydroxyurea causes the transformation of rodent embryo cells to a tumorigenic phenotype.

Hydroxyurea administered to male rats at 60 mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m2 basis) produced testicular atrophy, decreased spermatogenesis, and significantly reduced their ability to impregnate females.

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

The efficacy of DROXIA in sickle cell anemia was assessed in a large clinical study (Multicenter Study of Hydroxyurea in Sickle Cell Anemia) (see Table 2).

The study was a randomized, double-blind, placebo-controlled trial that evaluated 299 adult patients (≥18 years) with moderate to severe disease (≥3 painful crises yearly). The trial was stopped by the Data Safety Monitoring Committee, after accrual was completed but before the scheduled 24 months of follow-up was completed in all patients, based on observations of fewer painful crises among patients receiving hydroxyurea.

Compared to placebo treatment, treatment with hydroxyurea resulted in a significant decrease in the yearly rate of painful crises, the yearly rate of painful crises requiring hospitalization, the incidence of chest syndrome, the number of patients transfused, and units of blood transfused. Hydroxyurea treatment significantly increased the median time to both first and second painful crises.

Although patients with 3 or more painful crises during the preceding 12 months were eligible for the study, most of the benefit in crisis reduction was seen in the patients with 6 or more painful crises during the preceding 12 months.

Table 2:     Results from the Multicenter Study of Hydroxyurea in Sickle Cell Anemia
EventHydroxyurea
(N=152)
Placebo
(N=147)
Percent Change Versus PlaceboP-value
*   A painful crisis was defined in the study as acute sickling-related pain that resulted in a visit to a medical facility, that lasted more than 4 hours, and that required treatment with a parenteral narcotic or NSAID. Chest syndrome, priapism, and hepatic sequestration were also included in this definition.

Median yearly rate of painful crises*

2.5

4.6

−46

=0.001

Median yearly rate of painful crises requiring hospitalization

1.0

2.5

−60

=0.0027

Median time to first painful crisis (months)

2.76

1.35

+104

=0.014

Median time to second painful crisis (months)

6.58

4.13

+59

=0.0024

Incidence of chest syndrome (# episodes)

56

101

−45

=0.003

Number of patients transfused

55

79

−30

=0.002

Number of units of blood transfused

423

670

−37

=0.003

In patients with SCA treated with hydroxyurea, fetal hemoglobin (HbF) increases 4 to 12 weeks after initiation of treatment. In general, average HbF levels correlate with dose and plasma level with possible plateauing at higher dosages.

A clear relation between reduction in crisis frequency and increased HbF or F-cell levels has not been demonstrated. The dose-related cytoreductive effects of hydroxyurea, particularly on neutrophils, was the factor most strongly correlated with reduced crisis frequency.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

16.1 How Supplied

SPL UNCLASSIFIED SECTION

DROXIA® (hydroxyurea capsules, USP) is supplied in HDPE bottles with a plastic safety screw cap. Each bottle contains 60 capsules. DROXIA is supplied in the following strengths:

200 mg opaque blue-green capsules, marked in black ink with “DROXIA” and “6335” (NDC 0003-6335-17).

300 mg opaque purple capsules, marked in black ink with “DROXIA” and “6336” (NDC 0003-6336-17).

400 mg opaque reddish-orange capsules, marked in black ink with “DROXIA” and “6337” (NDC 0003-6337-17).

16.2 Storage

STORAGE AND HANDLING SECTION

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Keep tightly closed.

16.3 Handling and Disposal

SPL UNCLASSIFIED SECTION

DROXIA is a cytotoxic drug. Follow applicable special handling and disposal procedures [see References (15)].

To decrease the risk of contact, advise caregivers to wear disposable gloves when handling DROXIA or bottles containing DROXIA. Wash hands with soap and water before and after contact with the bottle or capsules when handling DROXIA. Do not open DROXIA capsules. Avoid exposure to crushed or opened capsules. If contact with crushed or opened capsules occurs on the skin, wash affected area immediately and thoroughly with soap and water. If contact with crushed or opened capsules occurs on the eye(s), the affected area should be flushed thoroughly with water or isotonic eyewash designated for that purpose for at least 15 minutes. If the powder from the capsule is spilled, immediately wipe it up with a damp disposable towel and discard in a closed container, such as a plastic bag; as should the empty capsules. The spill areas should then be cleaned three times using a detergent solution followed by clean water. Keep the medication away from children and pets. Contact your doctor for instructions on how to dispose of outdated capsules.

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

  • There is a risk of myelosuppression. Monitoring blood counts every two weeks throughout the duration of therapy should be emphasized to patients taking DROXIA. Advise patients to report signs and symptoms of infection or bleeding immediately [see Warnings and Precautions (5.1) ].
  • Advise patients of the risk of hemolytic anemia. Advise patients that they will have blood tests to evaluate for this if they develop persistent anemia. [see Warnings and Precautions (5.2) ].
  • Advise patients that there is a risk of cutaneous vasculitic toxicities and secondary malignancies including leukemia and skin cancers. Advise use of sun protection [see Warnings and Precautions (5.3, 5.5) ].
  • Advise patients to inform their healthcare provider if they have received or are planning to receive vaccinations while taking DROXIA as this may result in a severe infection [see Warnings and Precautions (5.6)].
  • Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy. Advise females and males of reproductive potential to use contraception during and after treatment with DROXIA [see Warnings and Precautions (5.4) and Use in Specific Populations (8.1, 8.3) ].
  • Advise females to discontinue breastfeeding during treatment with DROXIA [see Use in Specific Populations (8.2) ].
  • Patients with HIV infection should contact their physician for signs and symptoms of pancreatitis, hepatic events, and peripheral neuropathy [see Warnings and Precautions (5.7) ].
  • Advise patients of the symptoms of potential pulmonary toxicity and instruct them to seek prompt medical attention in the event of pyrexia, cough, dyspnea, or other respiratory symptoms [see Warnings and Precautions (5.9)].

SPL UNCLASSIFIED SECTION

Manufactured for:
Bristol-Myers Squibb Company
Princeton, New Jersey 08543 USA

SPL MEDGUIDE SECTION

 Medication Guide
DROXIA® (drock-SEE-yuh)
(hydroxyurea)
capsules

What is the most important information I should know about DROXIA?
DROXIA can cause serious side effects including:

  • Low blood counts are common with DROXIA, including low red blood cells, white blood cells, and platelets, and can be severe and life-threatening. If your white blood cell count becomes very low, you are at increased risk for infection. Your healthcare provider will check your blood cell counts before and during treatment with DROXIA. Your healthcare provider may change your dose or tell you to stop taking DROXIA if you have low blood cell counts. Tell your healthcare provider right away if you get any of the following symptoms:
  •  Fever
  •  feeling very tired
  •  chills
  •  shortness of breath
  •  body aches
  •  bleeding or unexplained bruising
  • Cancer. Some people have developed cancer, such as leukemia and skin cancer, after taking DROXIA for a long time. Your healthcare provider will check you for cancer. You should protect your skin from the sun using sunblock, hats, and sun-protective clothing.
  • DROXIA can harm your unborn baby.

For females taking DROXIA who can become pregnant:

  • You should talk with your healthcare provider about the risks of DROXIA to your unborn baby.
  • You should use effective birth control during treatment with DROXIA and for at least 6 months after treatment.
  • Your healthcare provider will perform a pregnancy test before you start treatment with DROXIA.
  • You should avoid becoming pregnant during treatment with DROXIA. Tell your healthcare provider right away if you become pregnant or think you may be pregnant. 

 For males taking DROXIA:

  • DROXIA can affect your sperm. If you have a female sexual partner who can become pregnant, you should use a condom during treatment with DROXIA and for at least 1 year after treatment.

 DROXIA may cause fertility problems in males. Talk to your healthcare provider if this is a concern for you.

See "What are the possible side effects of DROXIA?" for more information about side effects.

What is DROXIA?
DROXIA is a prescription medicine that is used to reduce the frequency of painful crises and reduce the need for blood transfusions in people with sickle cell anemia with recurrent moderate to severe painful crises.
It is not known if DROXIA is safe and effective in children.

Do not take DROXIA if you are allergic to hydroxyurea or any of the ingredients in DROXIA. See the end of this leaflet for a list of the ingredients in DROXIA.

Before taking DROXIA, tell your healthcare provider about all of your medical conditions, including if you:

  • have kidney problems or are receiving hemodialysis.
  • have human immunodeficiency virus (HIV). Taking DROXIA with certain HIV medicines can cause serious reactions and may lead to death. Tell your healthcare provider if you take an HIV medicine.
  • have increased level of uric acid in your blood (hyperuricemia).
  • have a history of receiving interferon therapy or are currently receiving interferon therapy.
  • have leg wounds or ulcers
  • plan to receive any vaccinations. You should not receive "live vaccines" during treatment with DROXIA.
  • are pregnant or plan to become pregnant. See "What is the most important information I should know about DROXIA?"
  • are breastfeeding or plan to breastfeed. DROXIA can pass into your breast milk. Do not breastfeed during treatment with DROXIA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I take DROXIA?

  • Take DROXIA exactly as your healthcare provider tells you. DROXIA is taken 1 time a day.
  • If you take too much DROXIA, call your healthcare provider or go to the nearest hospital emergency room right away.
  • DROXIA capsules must be handled with care. To decrease the risk of exposure, you or your caregivers should do the following when handling DROXIA:
  • Wear disposable gloves when handling DROXIA capsules or bottles containing DROXIA.
  • Wash your hands with soap and water before and after handling DROXIA capsules or bottles containing DROXIA.
  • Do NOT open, break, or chew the capsules.
  • Avoid contact with crushed or opened capsules. If contact from crushed or opened capsules happens on the skin, wash the skin area right away and thoroughly with soap and water. If contact from crushed or opened capsules happens in the eyes, flush the eyes thoroughly with water or isotonic eyewash used for that purpose for at least 15 minutes.
  • If the powder from the capsule is spilled, wipe it up right away with a damp disposable towel. Throw the damp disposable towel and the empty capsules away in a closed container, such as a plastic bag. The spill areas should then be cleaned three times using a detergent solution followed by clean water.

What are the possible side effects of DROXIA?
DROXIA may cause serious side effects, including:

  • See "What is the most important information I should know about DROXIA?"
  • Skin ulcers and death of tissue (gangrene) have happened in people who take DROXIA. This has happened most often in people who receive interferon therapy or have a history of interferon therapy. Your healthcare provider will stop treatment with DROXIA if you develop any skin ulcers.
  • Enlarged red blood cells (macrocytosis). Macrocytosis is common in people who take DROXIA and can make it difficult to detect a decrease of folic acid. Your healthcare provider may prescribe a folic acid supplement for you.
  • Hemolytic Anemia, the fast breakdown of red blood cells, has happened in people who take DROXIA. Tell your healthcare provider if you develop yellowing of your skin (jaundice) or blood in your urine. Your healthcare provider may do blood tests if you have persistent or worsening anemia.
  • Respiratory (breathing) problems. Some people have developed life-threatening respiratory conditions called interstitial lung disease. Your healthcare provider may tell you to stop taking DROXIA if you develop respiratory problems. Tell your healthcare provider right away if you get any of the following symptoms:
  •  fever                      
  •  shortness of breath
  •  cough

The most common side effects of DROXIA include:

  • reduced blood counts
  • bleeding
  • mouth ulcers
  • nausea
  • diarrhea or constipation
  • loss of appetite

These are not all the possible side effects of DROXIA.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store DROXIA?

  • Store DROXIA at room temperature between 68°F to 77°F (20°C to 25°C).
  • Keep the DROXIA bottle tightly closed.
  • Call your healthcare provider for instructions on how to throw away (dispose of) DROXIA that is out of date.

Keep DROXIA and all medicines out of the reach of children. Keep DROXIA away from pets.

General information about the safe and effective use of DROXIA
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use DROXIA for a condition for which it was not prescribed. Do not give DROXIA to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about DROXIA that is written for health professionals.

What are the ingredients of DROXIA?
Active ingredient: hydroxyurea
Inactive ingredients: citric acid, gelatin, lactose, magnesium stearate, sodium phosphate, titanium dioxide, and capsule colorants: FD&C Blue No. 1 and FD&C Green No. 3 (200 mg capsules); D&C Red No. 28, D&C Red No. 33, and FD&C Blue No. 1 (300 mg capsules); D&C Red No. 28, D&C Red No. 33, and D&C Yellow No. 10 (400 mg capsules).


Manufactured for: Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA
For more information, go to www.BMS.com or call 1-800-721-5072.

This Patient Information has been approved by the U.S. Food and Drug Administration.                           

                                                                                                       Revised: January 2022

DROXIA 200 mg capsules Representative Packaging

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

See How Supplied section for a complete list of available packages of DROXIA.

60 CAPSULES
NDC 0003-6335-17
DROXIA®
(hydroxyurea capsules, USP)
200 mg per capsule
Rx only
CAUTION: Cytotoxic Agent

Bristol-Myers Squibb

Droxia 200 mg Bottle Label
Droxia 200 mg Bottle Label

60 CAPSULES
NDC 0003-6335-17
DROXIA®
(hydroxyurea capsules, USP)
200 mg per capsule
Rx only
CAUTION: Cytotoxic Agent

Bristol-Myers Squibb

Droxia 200 mg Carton LabelDroxia 200 mg Carton Label

DROXIA 300 mg capsules Representative Packaging

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

60 CAPSULES
NDC 0003-6336-17
DROXIA®
(hydroxyurea capsules, USP)
300 mg per capsule
Rx only
CAUTION: Cytotoxic Agent

Bristol-Myers Squibb

Droxia 300 mg Bottle LabelDroxia 300 mg Bottle Label

60 CAPSULES
NDC 0003-6336-17
DROXIA®
(hydroxyurea capsules, USP)
300 mg per capsule
Rx only
CAUTION: Cytotoxic Agent

Bristol-Myers Squibb

Droxia 300 mg Carton LabelDroxia 300 mg Carton Label

DROXIA 400 mg capsules Representative Packaging

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

60 CAPSULES
NDC 0003-6337-17
DROXIA®
(hydroxyurea capsules, USP)
400 mg per capsule
Rx only
CAUTION: Cytotoxic Agent

Bristol-Myers Squibb

Droxia 400 mg Bottle LabelDroxia 400 mg Bottle Label

60 CAPSULES
NDC 0003-6337-17
DROXIA®
(hydroxyurea capsules, USP)
400 mg per capsule
Rx only
CAUTION: Cytotoxic Agent

Bristol-Myers Squibb

Droxia 400 mg Carton LabelDroxia 400 mg Carton Label

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0003-6335DROXIA (HYDROXYUREA) CAPSULE [E.R. SQUIBB & SONS, L.L.C.]19Legacy NDC20221129_740e054b-faac-7c27-f06d-a56efb699355.zip
0003-6336DROXIA (HYDROXYUREA) CAPSULE [E.R. SQUIBB & SONS, L.L.C.]19Legacy NDC20221129_740e054b-faac-7c27-f06d-a56efb699355.zip
0003-6337DROXIA (HYDROXYUREA) CAPSULE [E.R. SQUIBB & SONS, L.L.C.]19Legacy NDC20221129_740e054b-faac-7c27-f06d-a56efb699355.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0003-6336-17EA - Each0003-6336f14acbb7-7b26-4fe7-879d-6335a8d6137d12012-07-24
0003-6335-17EA - Each0003-63356295e8d6-c624-4ad1-b0b3-b85bd41f3f8a12012-07-24
0003-6337-17EA - Each0003-6337cae6a40c-d33d-421e-ba38-acb8fc4cedcc12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
hydroxyureaACTIVE INGREDIENTX6Q56QN5QC7
hydroxyureaACTIVE MOIETYX6Q56QN5QC7
citric acid monohydrateINACTIVE INGREDIENT2968PHW8QP7
D&C Red No. 28INACTIVE INGREDIENT767IP0Y5NH7
D&C Red No. 33INACTIVE INGREDIENT9DBA0SBB0L7
D&C Yellow No. 10INACTIVE INGREDIENT35SW5USQ3G7
FD&C Blue No. 1INACTIVE INGREDIENTH3R47K3TBD7
FD&C Green No. 3INACTIVE INGREDIENT3P3ONR6O1S7
gelatinINACTIVE INGREDIENT2G86QN327L7
lactoseINACTIVE INGREDIENTJ2B2A4N98G7
magnesium stearateINACTIVE INGREDIENT70097M6I307
sodium phosphateINACTIVE INGREDIENTSE337SVY377
titanium dioxideINACTIVE INGREDIENT15FIX9V2JP7

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 13 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0003-63360003-6336-17
0003-63350003-6335-17
0003-63370003-6337-17

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 29 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 7 · 379 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
gelatinGELATIN2G86QN327LGUM, CHEWING / BUCCAL102 mgExact identifier — unii candidate
44 equally ranked IID candidates
citric acid monohydrateCITRIC ACID MONOHYDRATE2968PHW8QPPOWDER, FOR SOLUTION / ORAL315 mgExact identifier — unii candidate
88 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPSUSPENSION / ORAL113 mgExact identifier — unii candidate
40 equally ranked IID candidates
gelatinGELATIN2G86QN327LINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR1 mgExact identifier — unii candidate
44 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GTABLET, FILM COATED / ORAL590 mgExact identifier — unii candidate
36 equally ranked IID candidates
sodium phosphateSODIUM PHOSPHATESE337SVY37CONCENTRATE / ORALNAExact identifier — unii candidate
24 equally ranked IID candidates
D&C Red No. 28D&C RED NO. 28767IP0Y5NHPOWDER, FOR SUSPENSION / ORAL0.7 mg/5mlExact identifier — unii candidate
11 equally ranked IID candidates
FD&C Green No. 3FD&C GREEN NO. 33P3ONR6O1SSYRUP / ORAL3.75 mg/5mlExact identifier — unii candidate
15 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GPOWDER / RESPIRATORY (INHALATION)90 mgExact identifier — unii candidate
36 equally ranked IID candidates
citric acid monohydrateCITRIC ACID MONOHYDRATE2968PHW8QPTABLET, COATED / ORALNAExact identifier — unii candidate
88 equally ranked IID candidates
FD&C Blue No. 1FD&C BLUE NO. 1H3R47K3TBDLOTION / TOPICALNAExact identifier — unii candidate
37 equally ranked IID candidates
FD&C Blue No. 1FD&C BLUE NO. 1H3R47K3TBDTABLET, SUGAR COATED / ORALNAExact identifier — unii candidate
37 equally ranked IID candidates
FD&C Blue No. 1FD&C BLUE NO. 1H3R47K3TBDCAPSULE, COATED PELLETS / ORALNAExact identifier — unii candidate
37 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30POWDER, FOR SUSPENSION / ORAL120 mgExact identifier — unii candidate
39 equally ranked IID candidates
D&C Yellow No. 10D&C YELLOW NO. 1035SW5USQ3GPOWDER / ORAL48 mgExact identifier — unii candidate
31 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30TABLET, CHEWABLE / ORAL127 mgExact identifier — unii candidate
39 equally ranked IID candidates
gelatinGELATIN2G86QN327LTABLET, SUGAR COATED / ORALNAExact identifier — unii candidate
44 equally ranked IID candidates
sodium phosphateSODIUM PHOSPHATESE337SVY37INJECTION, SOLUTION / INTRAMUSCULAR0.14 %w/vExact identifier — unii candidate
24 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30TABLET / ORAL980 mgExact identifier — unii candidate
39 equally ranked IID candidates
citric acid monohydrateCITRIC ACID MONOHYDRATE2968PHW8QPSOLUTION / INTRAVENOUS10 mgExact identifier — unii candidate
88 equally ranked IID candidates
FD&C Blue No. 1FD&C BLUE NO. 1H3R47K3TBDLIQUID / ORALNAExact identifier — unii candidate
37 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GGRANULE, FOR SUSPENSION / ORAL512.5 mg/5mlExact identifier — unii candidate
36 equally ranked IID candidates
D&C Red No. 33D&C RED NO. 339DBA0SBB0LCONCENTRATE / ORAL0.02 mg/1mlExact identifier — unii candidate
14 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPGUM, CHEWING / BUCCAL182 mgExact identifier — unii candidate
40 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GTABLET, FILM COATED, EXTENDED RELEASE / ORAL620 mgExact identifier — unii candidate
36 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPCAPSULE, LIQUID FILLED / ORAL12 mgExact identifier — unii candidate
40 equally ranked IID candidates
D&C Yellow No. 10D&C YELLOW NO. 1035SW5USQ3GTABLET, COATED / ORAL2.5 mgExact identifier — unii candidate
31 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPSHAMPOO, SUSPENSION / TOPICAL3 %w/vExact identifier — unii candidate
40 equally ranked IID candidates
citric acid monohydrateCITRIC ACID MONOHYDRATE2968PHW8QPSOLUTION / TOPICAL17 mgExact identifier — unii candidate
88 equally ranked IID candidates
D&C Yellow No. 10D&C YELLOW NO. 1035SW5USQ3GPASTE / DENTALNAExact identifier — unii candidate
31 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GSOLUTION / ORAL1682 mg/15mlExact identifier — unii candidate
36 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GTABLET / ORAL2500 mgExact identifier — unii candidate
36 equally ranked IID candidates
D&C Yellow No. 10D&C YELLOW NO. 1035SW5USQ3GPOWDER, FOR SUSPENSION / ORAL76 mgExact identifier — unii candidate
31 equally ranked IID candidates
FD&C Green No. 3FD&C GREEN NO. 33P3ONR6O1STABLET / ORAL240 mgExact identifier — unii candidate
15 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPTABLET, COATED / ORAL49 mgExact identifier — unii candidate
40 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30WAFER / ORAL66 mgExact identifier — unii candidate
39 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPTABLET, DELAYED RELEASE / ORAL66 mgExact identifier — unii candidate
40 equally ranked IID candidates
FD&C Blue No. 1FD&C BLUE NO. 1H3R47K3TBDSOLUTION / RECTAL0.01 %w/vExact identifier — unii candidate
37 equally ranked IID candidates
gelatinGELATIN2G86QN327LTABLET, DELAYED RELEASE / ORAL19 mgExact identifier — unii candidate
44 equally ranked IID candidates
citric acid monohydrateCITRIC ACID MONOHYDRATE2968PHW8QPSPRAY, METERED / NASAL2 mgExact identifier — unii candidate
88 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPGRANULE, FOR SUSPENSION / ORAL143 mgExact identifier — unii candidate
40 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPSOAP / TOPICAL1 %w/wExact identifier — unii candidate
40 equally ranked IID candidates
FD&C Blue No. 1FD&C BLUE NO. 1H3R47K3TBDFILM / SUBLINGUAL0.07 mgExact identifier — unii candidate
37 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPPOWDER / RESPIRATORY (INHALATION)2 mgExact identifier — unii candidate
40 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GCAPSULE, DELAYED RELEASE / ORAL231.84 mgExact identifier — unii candidate
36 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL47 mgExact identifier — unii candidate
39 equally ranked IID candidates
gelatinGELATIN2G86QN327LTABLET, ORALLY DISINTEGRATING / SUBLINGUAL13 mgExact identifier — unii candidate
44 equally ranked IID candidates
FD&C Blue No. 1FD&C BLUE NO. 1H3R47K3TBDCAPSULE, DELAYED RELEASE PELLETS / ORAL0.01 mgExact identifier — unii candidate
37 equally ranked IID candidates
lactoseLACTOSEJ2B2A4N98GINJECTION / INTRAVENOUS203.5 mgExact identifier — unii candidate
36 equally ranked IID candidates
citric acid monohydrateCITRIC ACID MONOHYDRATE2968PHW8QPSUSPENSION, EXTENDED RELEASE / ORAL140.8 mgExact identifier — unii candidate
88 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30POWDER / TOPICAL104 mgExact identifier — unii candidate
39 equally ranked IID candidates
FD&C Green No. 3FD&C GREEN NO. 33P3ONR6O1SSHAMPOO / TOPICAL0.09 %w/wExact identifier — unii candidate
15 equally ranked IID candidates
D&C Yellow No. 10D&C YELLOW NO. 1035SW5USQ3GSOAP / TOPICAL1.4 %w/wExact identifier — unii candidate
31 equally ranked IID candidates
citric acid monohydrateCITRIC ACID MONOHYDRATE2968PHW8QPINJECTION / INTRAMUSCULAR28 mgExact identifier — unii candidate
88 equally ranked IID candidates
FD&C Green No. 3FD&C GREEN NO. 33P3ONR6O1SSUPPOSITORY / RECTAL0.02 mgExact identifier — unii candidate
15 equally ranked IID candidates
magnesium stearateMAGNESIUM STEARATE70097M6I30TABLET, ORALLY DISINTEGRATING / ORAL187 mgExact identifier — unii candidate
39 equally ranked IID candidates
D&C Red No. 33D&C RED NO. 339DBA0SBB0LTABLET, FILM COATED / ORALNAExact identifier — unii candidate
14 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPDROPS / ORALNAExact identifier — unii candidate
40 equally ranked IID candidates
gelatinGELATIN2G86QN327LINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR14 mgExact identifier — unii candidate
44 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPCREAM / TOPICAL80 mgExact identifier — unii candidate
40 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 4 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N016295-001HYDREAHYDROXYUREA500MGCAPSULE / ORALABRLD, RS, Approved before 1982
N016295-002DROXIAHYDROXYUREA200MGCAPSULE / ORALRLD1998-02-25
N016295-003DROXIAHYDROXYUREA300MGCAPSULE / ORALRLD1998-02-25
N016295-004DROXIAHYDROXYUREA400MGCAPSULE / ORALRLD1998-02-25

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
N016295-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 5 · 180 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N016295-001HYDREA500MGCAPSULE / ORALABRLD, RS, Approved before 1982d4dbc9d85df4…
2026-11-14 07:37:172026-10N016295-002DROXIA200MGCAPSULE / ORALRLD1998-02-25d4dbc9d85df4…
2026-11-14 07:37:172026-10N016295-003DROXIA300MGCAPSULE / ORALRLD1998-02-25d4dbc9d85df4…
2026-11-14 07:37:172026-10N016295-004DROXIA400MGCAPSULE / ORALRLD1998-02-25d4dbc9d85df4…
2026-10-15 13:18:302026-09N016295-001HYDREA500MGCAPSULE / ORALABRLD, RS, Approved before 1982c2088c7a36db…
2026-10-15 13:18:302026-09N016295-002DROXIA200MGCAPSULE / ORALRLD1998-02-25c2088c7a36db…
2026-10-15 13:18:302026-09N016295-003DROXIA300MGCAPSULE / ORALRLD1998-02-25c2088c7a36db…
2026-10-15 13:18:302026-09N016295-004DROXIA400MGCAPSULE / ORALRLD1998-02-25c2088c7a36db…
2026-09-14 22:38:342026-08N016295-001HYDREA500MGCAPSULE / ORALABRLD, RS, Approved before 198284e616aacf4f…
2026-09-14 22:38:342026-08N016295-002DROXIA200MGCAPSULE / ORALRLD1998-02-2584e616aacf4f…
2026-09-14 22:38:342026-08N016295-003DROXIA300MGCAPSULE / ORALRLD1998-02-2584e616aacf4f…
2026-09-14 22:38:342026-08N016295-004DROXIA400MGCAPSULE / ORALRLD1998-02-2584e616aacf4f…
2026-08-18 06:07:402026-07N016295-001HYDREA500MGCAPSULE / ORALABRLD, RS, Approved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07N016295-002DROXIA200MGCAPSULE / ORALRLD1998-02-25caaa826d4ba7…
2026-08-18 06:07:402026-07N016295-003DROXIA300MGCAPSULE / ORALRLD1998-02-25caaa826d4ba7…
2026-08-18 06:07:402026-07N016295-004DROXIA400MGCAPSULE / ORALRLD1998-02-25caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N016295-001HYDREA500MGCAPSULE / ORALABRLD, RS, Approved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02N016295-002DROXIA200MGCAPSULE / ORALRLD1998-02-25011fe1cb6892…
2026-02-19 14:30 UTC2026-02N016295-003DROXIA300MGCAPSULE / ORALRLD1998-02-25011fe1cb6892…
2026-02-19 14:30 UTC2026-02N016295-004DROXIA400MGCAPSULE / ORALRLD1998-02-25011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N016295-001HYDREA500MGCAPSULE / ORALABRLD, RS, Approved before 198231067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N016295-002DROXIA200MGCAPSULE / ORALRLD1998-02-2531067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N016295-003DROXIA300MGCAPSULE / ORALRLD1998-02-2531067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N016295-004DROXIA400MGCAPSULE / ORALRLD1998-02-2531067a03dcf5…
2025-08-23 18:47 UTC2025-08N016295-001HYDREA500MGCAPSULE / ORALABRLD, RS, Approved before 19826a471c1ec25d…
2025-08-23 18:47 UTC2025-08N016295-002DROXIA200MGCAPSULE / ORALRLD1998-02-256a471c1ec25d…
2025-08-23 18:47 UTC2025-08N016295-003DROXIA300MGCAPSULE / ORALRLD1998-02-256a471c1ec25d…
2025-08-23 18:47 UTC2025-08N016295-004DROXIA400MGCAPSULE / ORALRLD1998-02-256a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N016295-001HYDREA500MGCAPSULE / ORALABRLD, RS, Approved before 1982fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N016295-002DROXIA200MGCAPSULE / ORALRLD1998-02-25fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N016295-003DROXIA300MGCAPSULE / ORALRLD1998-02-25fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N016295-004DROXIA400MGCAPSULE / ORALRLD1998-02-25fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N016295-001HYDREA500MGCAPSULE / ORALABRLD, RS, Approved before 1982b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N016295-002DROXIA200MGCAPSULE / ORALRLD1998-02-25b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N016295-003DROXIA300MGCAPSULE / ORALRLD1998-02-25b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N016295-004DROXIA400MGCAPSULE / ORALRLD1998-02-25b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N016295-001HYDREA500MGCAPSULE / ORALABRLD, RS, Approved before 198203ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N016295-002DROXIA200MGCAPSULE / ORALRLD1998-02-2503ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N016295-003DROXIA300MGCAPSULE / ORALRLD1998-02-2503ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N016295-004DROXIA400MGCAPSULE / ORALRLD1998-02-2503ed91905a0d…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10N016295-001AB1d4dbc9d85df4…
2026-10-15 13:18:302026-09N016295-001AB1c2088c7a36db…
2026-09-14 22:38:342026-08N016295-001AB184e616aacf4f…
2026-08-18 06:07:402026-07N016295-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N016295-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N016295-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08N016295-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N016295-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N016295-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N016295-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N016295-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N016295-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N016295-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N016295-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N016295-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N016295-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N016295-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N016295-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N016295-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N016295-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N016295-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N016295-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03N016295-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N016295-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N016295-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03N016295-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N016295-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11N016295-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12N016295-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09N016295-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07N016295-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N016295-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N016295-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12N016295-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N016295-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N016295-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N016295-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N016295-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05N016295-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01N016295-001AB13bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
4e5c3df1-3e9c-4eb1-959e-1ab30dbb84f2740e054b-faac-7c27-f06d-a56efb6993552022-11-15Boxed warning, Warnings, Adverse reactionsExact identifier
spl id: 4e5c3df1-3e9c-4eb1-959e-1ab30dbb84f2
spl set id: 740e054b-faac-7c27-f06d-a56efb699355

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.